» Articles » PMID: 36555090

Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Dec 23
PMID 36555090
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is a monoclonal gammopathy characterized by biological heterogeneity and unregulated proliferation of plasma cells (PCs) in bone marrow (BM). MM is a multistep process based on genomic instability, epigenetic dysregulation and a tight cross-talk with the BM microenvironment that plays a pivotal role supporting the proliferation, survival, drug-resistance and homing of PCs. The BM microenvironment consists of a hematopoietic and a non-hematopoietic compartment, which cooperate to create a tumor environment. Among the non-hematopoietic component, mesenchymal stromal cells (MSCs) and osteoblasts (OBs) appear transcriptionally and functionally different in MM patients compared to healthy donors (HDs) and to patients with pre-malignant monoclonal gammopathies. Alterations of both MSCs and OBs underly the osteolytic lesions that characterize myeloma-associated bone disease. In this review, we will discuss the different characteristics of MSCs and OBs in MM patients, analyzing the transcriptome, the deregulated molecular pathways and the role performed by miRNAs and exosome in the pathophysiology of MM.

Citing Articles

Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells.

Pelon M, Krzeminski P, Tracz-Gaszewska Z, Misiewicz-Krzeminska I Front Pharmacol. 2024; 15:1351565.

PMID: 38500772 PMC: 10944964. DOI: 10.3389/fphar.2024.1351565.


The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease.

Lungu O, Toscani D, Burroughs-Garcia J, Giuliani N Int J Mol Sci. 2023; 24(5).

PMID: 36902326 PMC: 10003241. DOI: 10.3390/ijms24054893.

References
1.
Awada H, Thapa B, Awada H, Dong J, Gurnari C, Hari P . A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. Cells. 2021; 10(8). PMC: 8391934. DOI: 10.3390/cells10081961. View

2.
Palma B, Guasco D, Pedrazzoni M, Bolzoni M, Accardi F, Costa F . Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20. Leukemia. 2015; 30(2):409-16. DOI: 10.1038/leu.2015.259. View

3.
Orom U, Nielsen F, Lund A . MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008; 30(4):460-71. DOI: 10.1016/j.molcel.2008.05.001. View

4.
Zhao W, Yang H, Chai J, Xing L . RUNX2 as a promising therapeutic target for malignant tumors. Cancer Manag Res. 2021; 13:2539-2548. PMC: 7981165. DOI: 10.2147/CMAR.S302173. View

5.
Bolzoni M, Toscani D, Storti P, Marchica V, Costa F, Giuliani N . Possible targets to treat myeloma-related osteoclastogenesis. Expert Rev Hematol. 2018; 11(4):325-336. DOI: 10.1080/17474086.2018.1447921. View